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chronic liver disease and/or cirrhosis. Thus, chemoprevention
in individuals at risk represents an important but yet unproven
approach. In this study, we investigated the ability of micro-
RNA (miRNA)-based molecules to prevent liver cancer devel-
opment in a cirrhotic model. To this end, we developed amouse
model able to recapitulate the natural progression from fibrosis
to HCC, and then we tested the prophylactic activity of an
miRNA-based approach in the model. The experiments were
carried out in the TG221 transgenic mouse, characterized by
the overexpression of miR-221 in the liver and predisposed to
the development of liver tumors. TG221 as well as wild-type
mice were exposed to the hepatotoxin carbon tetrachloride
(CCl4) to induce chronic liver damage. All mice developed liver
cirrhosis, but only TG221 mice developed nodular lesions in
100% of cases within 6 months of age. The spectrum of lesions
ranged from dysplastic foci to carcinomas. To investigate
miRNA-based prophylactic approaches, anti-miR-221 oligonu-
cleotides or miR-199a-3p mimics were administered to TG221
CCl4-treated mice. Compared to control animals, a significant
reduction in number, size, and, most significantly, malignant
phenotype of liver nodules was observed, thus demonstrating
an important prophylactic action of miRNA-based molecules.
In summary, in this article, we not only report a simple model
of liver cancer in a cirrhotic background but also provide evi-
dence for a potential miRNA-based approach to reduce the
risk of HCC development.Received 6 July 2018; accepted 26 November 2018;
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Hepatocellular carcinoma (HCC) is the second leading cause of can-
cer-related death worldwide.1 Liver cirrhosis is the main risk factor
for HCC, as approximately 80% of tumors develop in individuals
with advanced liver fibrosis or cirrhosis.2 Viral hepatitis B and C
and alcohol abuse are the main causes of cirrhosis and liver cancer;
however, non-alcoholic fatty liver disease and steatohepatitis areMolecular The
This is an open access article under temerging contributing factors for this disease in developed
countries.3,4
Therapeutic approaches in patients with HCCmostly depend on liver
function and tumor extension, and they include surgery, percuta-
neous ablation, chemoembolization, and radioembolization.5 Sorafe-
nib, the only approved systemic therapy for patients with unresectable
advanced-stage HCC, provides only a small improvement in patients’
survival.6,7 Additional targeting agents have been tested, alone or in
combination with sorafenib, to improve HCC therapies with limited
survival benefits.8–10 Thus, new therapeutic approaches are certainly
needed; but, given the existence of a well-defined at-risk population,
chemoprevention represents another important but yet unproven
approach.
The pivotal role of microRNAs (miRNAs) in cancer11 opened new av-
enues for clinical applications. Indeed, for their ability to regulate on-
cogenes and tumor suppressor genes, miRNA-based therapies have
emerged as promising anti-cancer strategies.12 In HCC, miR-221 is
overexpressed in approximately 70%–80% of human cases, and it is
known to downregulate the expression of multiple gene targets rele-
vant for cancer, such as the cyclin-dependent kinase inhibitors p27
and p57, the phosphatase and tensin homolog (PTEN), or the BH3-
only pro-apoptotic protein BMF.13–15 We have validated the impor-
tance of miR-221 in liver tumorigenesis by developing the TG221rapy: Nucleic Acids Vol. 14 March 2019 ª 2018 The Author(s). 239
he CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Carbon Tetrachloride Treatment Induces
Cirrhosis in Wild-Type and TG221 Mice
(A) Liver cirrhosis was induced in TG221 (TG) and wild-
type (WT) mice by short carbon tetrachloride (CCl4) inha-
lation cycles, as described in the Materials and Methods.
(B) Both WT and TG221 mice were monitored for the
presence of hepatic lesions using an ultrasound diag-
nostic device during the weeks following the induction
protocol. The presence of liver fibrosis and cirrhosis was
evident in mice from both groups. The image is from a
CCl4-treated TG221 mouse; ascites in the peritoneal
cavity (red arrow) and irregular liver margins (white arrow)
are shown. In addition, the presence of liver nodules was
clearly evident (black arrows). (C) A significant accumu-
lation in ascitic fluids in the peritoneal cavity, based on the
total amount of ascites at the time of sacrifice, occurred in
both WT and TG221 mice, with respect to that in the
untreated control groups (p value < 0.001 for both
groups). (D) Similarly, the quantification of fibrotic areas
showed a comparable amount of liver fibrotic tissue
between WT and TG221 mice, but a significant difference
between these groups and control (CTRL) mice
(p value < 0.001 for both groups). Data are represented as
mean values ± SD. Representative images of Sirius Red
staining, specific for collagen accumulation, in histological
liver sections of untreated WT (E), untreated TG221 (F),
CCl4-treated WT (G), and CCl4-treated TG221 (H) mice
are shown. Scale bar, 500 mm. In the image, TG221 is
indicated as TG.
Molecular Therapy: Nucleic Acidstransgenic mouse, which is characterized by an inappropriate overex-
pression of miR-221 in the liver, emergence of spontaneous nodular
liver lesions in approximately 50% of male mice at 12 months of age,
and accelerated development of HCC upon treatment with diethylni-
trosamine (DEN).16 Another important miRNA, miR-199a-3p, is
downregulated in virtually all HCCs,17 and it is involved in the con-
trol of several cancer-associated genes, such as mechanistic target of
rapamycin (mTOR), the hepatocyte growth factor receptor MET,
the kinase p21-activated kinase 4 (PAK4), and the Notch regulator
YAP1.18–20. The anti-tumor activity of anti-miR-221 and miR-
199a-3p molecules on HCC has been demonstrated using in vivo
mouse models.16,20–23
The availability of animal models that reproduce human liver carci-
nogenesis is of essential importance for preclinical testing. Many of
such models have provided relevant information regarding molecular
and pathological mechanisms of HCC.24–26 However, one limitation
of the available animal models is that they commonly develop HCC in
the absence of cirrhosis. This might negatively affect the assessment of240 Molecular Therapy: Nucleic Acids Vol. 14 March 2019novel systemic therapies with respect to their
translation to typical human conditions. One
well-established method to induce liver damage
and promote fibrosis and cirrhosis in rats is a
chronic exposure to the hepatotoxin carbon
tetrachloride (CCl4).
27 In mice, achieving
advanced cirrhosis with ascites is more difficult,as prolonged exposure to the toxin affects animal survival.28 Domeni-
cali and colleagues29 described the use of short-term inhalation cycles
of CCl4 as an efficient method to induce decompensated cirrhosis in
mice.
In the present study, we used the method of Domenicali et al.29 on
TG221 transgenic mice to test the possibility of inducing liver tumors
in the context of cirrhosis. The model was then used for investigating
the prophylactic activity of anti-miR-221 as well as miR-199a-3p
molecules.
RESULTS
CCl4 Treatment Induces Cirrhosis and Ascitic Decompensation
in Mice
TG221 (TG) and wild-type (WT) mice of the same background strain
B6D2 (a cross between C57BL/6J [B6]  DBA/2J [D2]) were treated
with CCl4, following an administration protocol described by Dome-
nicali et al.,29 which consists of multiple short cycles of CCl4 inhala-
tion (Figure 1A). During the 14-week induction phase, mice displayed
Figure 2. CCl4 Treatment Promotes Cirrhosis and Tumor Formation in the
Livers of TG221 Mice
Representative macroscopic and ultrasound images of livers from untreatedWT (A),
CCl4-treated WT (B), untreated TG221 (C), and CCl4-treated TG221 (D) mice. Livers
of untreated TG221 andWTmice look a little different, as the aberrant expression of
miR-221 in the liver of TG221 is responsible for an increase in volume and a pale
exterior associated with steatohepatitis changes, as previously described.16 Livers
of CCl4-treated mice presented a cirrhotic appearance with a granulated surface. At
the time of sacrifice, macroscopic nodules were evident in the livers of 100% of
TG221 mice (as indicated by red arrows), but not in WT mice. Ultrasound images
show the presence of ascites (yellow arrows) in both CCl4-treated WT and TG221
mice, while liver nodules were only visible in TG221 mice (delimited by plus symbol
and indicated by red arrows). Conversely, untreated WT and TG221 mice show
homogeneous liver parenchyma, with no ascites or nodules. (E) The numbers of
www.moleculartherapy.orgno signs of suffering, as shown by an increase in body weight over
time for both experimental groups (Figure S1).
WT and TG221 mice were monitored for the presence of hepatic le-
sions using an ultrasound device. Both groups of mice exhibited signs
of liver fibrosis and cirrhosis, as shown by irregular liver margins and
peritoneal effusions after 12–14 weeks of treatment (Figure 1B). All
mice were sacrificed 10 weeks after the end of CCl4 treatment. Consis-
tent with ultrasound imaging, the livers of all animals exposed to CCl4
had cirrhotic features with micronodular pale surfaces. Quantifica-
tion of ascites revealed no significant differences between TG221
and WT animals, demonstrating the successful induction of cirrhosis
in both groups. Upon histologic examination, Sirius Red staining
showed bridging fibrosis in both TG221 andWTmice, but not in un-
treatedmice (Figures 1C–1H). Moreover, activation of hepatic stellate
cells was confirmed by the overexpression of a-smooth muscle actin
(a-Sma), connective tissue growth factor (Ctgf), and transforming
growth factor beta 1 (Tgf-b1) (Figure S2).
CCl4 Treatment Leads to Cancer Formation in TG221 Mice
A significant difference in liver pathology was observed between WT
and TG221 mice. At 4 weeks from the end of CCl4 treatment, ultra-
sound analysis revealed the presence of liver nodules in TG221, but
not in WT, mice. Upon sacrifice, macroscopic nodules were indeed
visible in the livers of all TG221 mice, but not in WT mice (Figures
2A–2D).
Histological analyses confirmed a significant increase in the number
and size of focal lesions in the livers of CCl4-treated TG221 mice
compared to those in WT controls (Figure 2E). Most lesions in
TG221 mice were dysplastic nodules or HCC, whereas in WT mice
most were macro-regenerative or hyperplastic nodules (Table 1; Fig-
ures S3 and S4). The livers of WT CCl4-treated mice showed the loss
of an ordered lobular architecture with bridging fibrosis. In this back-
ground, hepatocytes aggregated into regenerative-proliferative lesions,
displayed typical mitosis, and did not contain dysplastic components
(Figures 3A–3C). In TG221 mice, necro-inflammatory changes ap-
peared to be more intense and extended, and the degenerative compo-
nents of hepatocytes were marked and associated with both lithic and
coagulative necrotic effects. Notably, progression to malignant tumors
was detected based on the development of nodule-in-nodule prolifera-
tion, characterized by nuclear atypia, mitoses, increased trabecular
width, and infiltrative growth (Figures 3D–3F; Figure S4).
In support of the malignant nature of tumors fromCCl4-treated mice,
we investigated the expression of genes, such as alpha-fetoprotein
(Afp), trefoil factor 3 (Tff3), stearoyl-coenzyme A desaturase 2
(Scd2), lipoprotein lipase (Lpl), and glypican 3 (Gpc3), which are
known markers of hepatic tumor progression.30,31 As positive con-
trols for mouse HCC, we used samples from control DEN-inducednodules detected by histopathological examination were significantly higher in
TG221 mice than in CCl4-treated WT mice (p value < 0.001). In the image, TG221 is
indicated as TG.
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Table 1. Histopathological Examination of Liver Tissues
Genotype Mouse ID Diagnosis
Wild-type
WT-1 hyperplasia
WT-2 hyperplasia
WT-3 hyperplasia
WT-4 hyperplasia
WT-5 hyperplasia
TG221
TG-1 dysplasia
TG-2 HCC
TG-3 HCC
TG-4 dysplasia
TG-5 HCC
TG-6 HCC
TG-7 dysplasia
TG-8 HCC
TG-9 HCC
TG-10 HCC
Molecular Therapy: Nucleic AcidsHCC obtained in TG221 mice in previous studies.16,20 The level of
expression was progressively increased from normal liver, cirrhotic
tissue, CCl4-induced tumors, and DEN-induced HCC (Figure 4A).
In addition, by using a wider gene panel that included the above genes
as well as additional genes described as markers of proliferating and
self-renewing liver cells,32 we observed that, while the heatmap
from an unsupervised analysis shows that the HCCs from CCl4-
treated mice cluster with cirrhotic livers (Figure 4B; Table S1), it
should also be noted that a group of genes (Afp, Scd2, Gpc3, Prom1,
Lpl, Ttf3, and Mcm2) exhibit an expression profile more similar to
DEN-induced HCC than to cirrhotic livers, thus indicating a progres-
sion to cancer of CCl4-induced tumors. These data indicate that these
latter tumors maintain a cirrhotic signature but already evolved to-
ward a malignant signature, thus confirming the results from histo-
pathological analyses.
Prophylactic Treatment with Anti-miR-221 Oligonucleotides or
miR-199a-3p Mimics Prevents the Development of Malignant
Lesions
As the model used herein recapitulates the phases of human HCC
arising in cirrhotic liver, we investigated the ability of miRNA-based
molecules to prevent or control cancer development. Three experi-
mental groups were designed: (1) mice treated with miR-199a-3p,
(2) mice treated with anti-miR-221 (AM221), and (3) a control group
treated with a scrambled oligonucleotide. Treatments were performed
according to a protocol shown in Figure 5A. During treatments, mice
were monitored by ultrasound to evaluate tumor appearance and
growth. Compared to controls, we observed a reduction in tumor
growth, including the complete inhibition or regression of tumor
nodules, in the group of animals treated with miRNA-based mole-
cules (Figure S5).242 Molecular Therapy: Nucleic Acids Vol. 14 March 2019At the time of sacrifice, tumor nodules in the livers of mice treated
with miRNA-based molecules were macroscopically smaller than
those in the control group (Figures 5B–5D). A reduction in the
liver-to-body weight ratio observed in animals treated with AM221
or miR-199a-3p, compared to that in controls, confirmed the reduced
tumor burden (Figure 5E).
Histological analyses confirmed that the livers of miRNA-treated an-
imals contained a smaller number of proliferative foci. Notably,
HCCs were detected in at least four of the nine control mice,
whereas only one HCC was detected among all miRNA-treated
mice (Table S2). Treated mice also showed evidence of reduced liver
damage, as assessed by hydropic changes, number of necro-inflam-
matory foci, and/or confluent necrosis (Figure 5C). A reduction in
the level of Gpc3 expression could also be noted in livers of
AM221-treated mice (Figure S6).
In parallel with the observed macroscopic and microscopic changes,
miR-199a-3p and anti-miR-221 were found to induce molecular
changes. Indeed, the levels of protein targets of these miRNAs were
changed, as assessed by the western blot analysis of cirrhotic tissues
and tumor nodules. Specifically, the downregulation of mTOR and
PAK4 was observed after treatment with miR-199a-3p (Figure 6A);
the upregulation of PTEN and cyclin-dependent kinase inhibitor
1B (CDKN1B -P27) was also observed after treatment with AM221
(Figure 6B). These results confirmed that miRNA-based treatments
were associated with molecular effects on important cancer-associ-
ated pathways.
DISCUSSION
This work describes a new mouse model that recapitulates the prog-
ress of chronic liver disease from fibrosis and cirrhosis to HCC and
miRNA-based approaches for the prevention of liver cancer in a
cirrhotic liver. This is particularly relevant as approximately 80% of
HCCs occur in patients with an underlying cirrhosis.
The availability of an optimal animal model that faithfully mimics
the human disease can help to achieve results applicable to humans.
Current HCC mouse models do not generally encompass liver
fibrosis and cirrhosis. Treatment with CCl4 was previously shown
to induce liver fibrosis and cirrhosis in rats and mice, but only
sporadically did animals develop liver cancer. Experimental models
of decompensated cirrhosis are well established in rats,28,33,34 but
only additional repeated injections of low-dose DEN result in the
development of HCC in these animals.35,36 Mouse models that
develop HCC in a background of fibrosis or cirrhosis have also
been produced by a combination of DEN and CCl4 induction.
37–39
However, prolonged exposure to the hepatotoxin negatively affects
animal survival.28 Additional models of HCC concomitant with
liver cirrhosis included CCl4 administration combined with ortho-
topic tumor implantation or with adenoviral Cre-recombinase injec-
tion in genetically engineered mouse models.40 In a more recent
study, the concomitant CCl4 treatment with the injection of trans-
posons expressing Myc and a short hairpin RNA that downregulates
Figure 3. CCl4-Treated TG221 Mice Present Neoplastic Proliferative Lesions
H&E-stained livers from untreated and CCl4-treated mice (200 and 40 magnification). In WT mice (A–C), alterations in the lobular structure of the liver and hepatic
degeneration, with the presence of regenerative nodules typical of hepatic cirrhosis, were detected in CCl4-treated animals (A and B), but not in untreated mice (C). In TG221
mice (D–F), the same structural alterations in WT animals were observed in CCl4-treated animals (D and E), with a higher and more intense grade of inflammation. In addition,
proliferative tumor lesions were present (black arrows, D) and associated with dysplastic aspects and atypical mitosis (black arrows, E), resembling hepatocellular carci-
nomas. (F) These alterations were absent in livers from untreated TG221 mice, albeit steatohepatitis changes, typical of the TG221 mouse,16 were observed.
www.moleculartherapy.orgp53 (shp53) resulted in 100% HCC incidence accompanied by liver
fibrosis.41
The TG221-CCl4 model reported here is based on a simpler approach,
as it only requires CCl4 administration, using the method described by
Domenicali et al.,29 to induce decompensated cirrhosis in the TG221
mouse strain. TG221 mice develop cirrhosis with ascitic decompensa-
tion, accompanied by cancer development in 100% of animals. Liver
histology revealed disrupted lobular architecture, bridging fibrosis,
and necro-inflammatory liver damage. Liver fibrogenesis was
confirmed by the increased deposition of collagen and the increased
expression of a-Sma, a specific marker of hepatic stellate cell activa-
tion,42 in addition to the upregulation of Tgf-b and Ctgf pro-fibrotic
molecules.43,44 The neoplastic nature of the hepatocellular nodules
was confirmed by histology, which identified a spectrum of lesions
ranging fromdysplastic foci or nodules toHCC.The expressionof genes
such as Afp, Tff3, Lpl, Scd2, andGpc3, which are involved in liver carci-
nogenesis, further supported the presence of a malignant phenotype.
Because the TG221-CCl4mouse recapitulates all the phases of chronic
liver disease, from fibrosis to HCC, it provides a new excellent model
for testing treatments aimed at the prevention of HCC. Chemopre-
ventive agents may act at various phases of chronic liver disease to
prevent its progression to HCC. In humans, immunization against
hepatitis B virus (HBV) and antiviral therapy against HBV and hep-
atitis C virus (HCV) have been associated with reduced HCC risk. Inaddition, statins, aspirin, and the anti-diabetic agent metformin have
also shown promising chemopreventive activity.45,46 In animals, most
of the studies were carried out in the therapeutic setting;47 nonethe-
less, a number of compounds exhibited chemopreventive effects.
They included natural plant products such as curcumin, resveratrol,
epigallocatechin, caffeine,48–50 anti-fibrotic agents,51 COX-2 inhibi-
tors,52 and S-adenosylmethionine.53
Here we tested miRNA-based molecules for the prevention of liver
cancer. The restoration of tumor suppressor miRNAs or inhibition
of oncogenic miRNAs have been previously tested in the therapeutic
experimental setting in a number of pre-clinical models, including
liver cancer.54,55 Based on previous studies, miR-221 and miR-
199a-3p represented suitable candidates.16,20 The importance of
miR-221 to liver tumorigenesis was described in orthotopic and
transgenic HCC mouse models,16,56 and its oncogenic function was
associated with the ability to promote cell proliferation and inhibit
apoptosis.13,14 As such, silencing miR-221 in vivowas found to reduce
tumor growth, increase mouse survival,16,57 and inhibit the establish-
ment of hepatoma xenografts and lung metastasis in nude mice.58
miR-199a-3p is one of the most highly expressed miRNAs in normal
liver and is downregulated in virtually all HCCs.17,22 This miRNA has
a pivotal role in several cancer-associated pathways.19,22,59,60 The
restoration of miR-199a-3p expression in subcutaneous or orthotopic
HCC mouse models demonstrated its anti-tumor activity, suggesting
that miR-199a-3p replacement might represent a promisingMolecular Therapy: Nucleic Acids Vol. 14 March 2019 243
Figure 4. Tumor-Associated Genes Are Similarly
Deregulated in CCl4-Induced and
Diethylnitrosamine-Induced TG221 Liver Tumors
(A) The tumor-associated genes Afp, Tff3, Scd2, Lpl, and
Gpc3were highly expressed in TG221 liver tumors in both
cirrhotic and non-cirrhotic conditions. A clear progression
in their expression level was also observed from normal
livers to cirrhotic livers and CCl4-induced or diethylni-
trosamine (DEN)-induced HCC. The p values refer to
mRNA expression levels in cirrhotic (CL) and HCC con-
ditions versus those in normal livers (NL). The scale on the
ordinate axis refers to mRNA expression related to that in
normal livers. (B) Unsupervised hierarchical cluster anal-
ysis of gene expression to assess similarities between
tumors arising in TG221 mice after DEN treatment versus
those induced by CCl4 treatment. Most TG221 DEN-
derived tumors (HCC DEN-TG) were found to be carci-
nomas. Normal livers (NL-WT), cirrhotic livers (CL-WT),
and DEN-derived tumors (HCC DEN-WT) from WT mice
were also included in this analysis. The analysis was
performed using a list of genes described as markers of
hepatic tumor progression as well as markers of prolifer-
ating and self-renewing liver cells. HCC CCl4 samples
exhibited an expression profile that was highly similar to
that of HCC DEN samples, whereas cirrhotic livers from
TG221 mice (CL-TG) displayed an intermediate expres-
sion pattern between that of HCC and normal liver. Color
legend is as follows: NL-WT, pink boxes; CL-WT, light
blue boxes; HCC DEN-WT, blue boxes; NL-TG, red
boxes; CL-TG, black boxes; HCC DEN-TG, green boxes;
and HCC CCl4-TG, gray boxes. Abbreviations are as
follows: Afp, alpha fetoprotein; Scd2, stearoyl-Coenzyme
A desaturase 2;Gpc3, glypican 3; Prom1, prominin 1; Lpl,
lipoprotein lipase; Tff3, trefoil factor 3; Mcm2, mini-
chromosome maintenance-deficient 2 mitotin; Met, met
proto-oncogene; Yap1, yes-associated protein 1; Mst1,
macrophage-stimulating 1 (hepatocyte growth factor-
like);CD44, CD44 antigen;Hgf, hepatocyte growth factor;
Tacstd2, tumor-associated calcium signal transducer 2;
Vim, Vimentin; Il6, interleukin-6; and Bmp2, bone
morphogenetic protein 2. In the image, TG221 is indicated
as TG.
Molecular Therapy: Nucleic Acidstherapeutic strategy to treat HCC.20,22,59–62 In this work, we focused
on the ability of each of these miRNAs to prevent tumor development
using the TG221-CCl4 mouse model. Systemic administration of
either anti-miR-221 or miR-199a-3p mimics resulted in a reduction
in the malignant progression of hepatocellular nodules.
Biological outcomes were accompanied by detectable molecular
effects that allowed us to recognize and confirm cancer-associated
signaling pathways regulated by miR-199a-3p and miR-
221.14,15,18,22 In fact, the enforced expression of miR-199a-3p elicited
the downregulation of mTOR and PAK4 proteins, while the suppres-
sion of miR-221 by anti-miRNA caused the upregulation of PTEN
and CDKN1B. PAK4, a serin-threonine kinase member of the PAK
family,63 is at the crossroads of several oncogenic pathways. It func-
tions as Rho’s GTPase effector to reorganize the cytoskeleton: it is
indeed activated by Cdc42 to promote cell motility through the for-244 Molecular Therapy: Nucleic Acids Vol. 14 March 2019mation of lamellipodia and filopodia. PAK4 can also act on other tar-
gets: it opposes the activation of caspase 8, promotes stabilization and
activation of b-catenin, and through its scaffold function stimulates
AKT activation.64–67 In a variety of human cancers, PAK4 is overex-
pressed, amplified, or is affected by mutations that activate its kinase
activity.68–72 mTOR, an essential protein for the activation of the
PI3K-AKT pathway, is a serin-threonine kinase that, in complex
with RICTOR, phosphorylates and activates AKT; in complex with
RAPTOR, it is phosphorylated by AKT to regulate protein synthesis,
growth, proliferation, and cell survival.73
The PI3K-AKT pathway is frequently activated by mutations of genes
such as RAS, PI3KCA, or PTEN, which are, however, rare in HCC. In
HCC, in addition tomiRNAderegulation, this pathway is instead acti-
vated by numerous growth factors, such as hepatocyte growth factor
(HGF), platelet-derived growth factor (PDGF), and vascular
Figure 5. miR-199a-3p Mimics and Anti-miR-221
Molecules Exhibit Prophylactic Activity in the TG221
Model
(A) The experimental design was subdivided into a CCl4
induction period of 14 weeks and a prophylactic miRNA-
based treatment period. Specifically, after 10 weeks of
CCl4 induction, one group of mice received a weekly dose
of anti-miR-221 (AM221) for 10 weeks and another group
received a dose of miR-199a-3p mimic three times per
week for 12 weeks. AM221-treated mice were sacrificed
2 weeks after the last treatment, due to the longer stability
of the anti-miRNA molecules, whereas miR-199a-3p-
treated mice were sacrificed 24 hr after the last mimic
injection. A group of mice treated with a scramble oligo-
nucleotide was employed as the negative control (CTRL).
(B) Representative macroscopic images of livers from
scramble-treated mice (CTRL), miR-199a-3p-treatd mice
(miR-199a-3p) and AM221-treated mice (AM221) at the
time of sacrifice. (C) Hematoxylin and eosin stained livers
from the samemice described above (40magnification).
Liver nodules in control animals showed malignant pro-
gression to hepatocellular carcinoma (HCC) accompanied
by a loss of fatty changes, increased nuclear: cytoplasmic
ratio, nuclear atypia, and easily detectable mitotic activity;
treated mice had dysplastic nodules with fatty and focal
nodular hyperplasia-like changes. (D) The panel shows
the average size of tumor lesions in each mouse and
demonstrates how they are significantly reduced after
miRNA-therapy treatment. (E) Liver-to-body weight ratios
are lower (p value = 0.009 in AM221-treated animals) or
tended to be lower (p value not significant in miR-199a-
3p-treated mice) in treated animals than in controls.
www.moleculartherapy.orgendothelial growth factor (VEGF), present in the tumor microenvi-
ronment, or by the amplification of genes coding for fibroblast growth
factor (FGF; in particular FGF19, 5%–14% of HCC cases).74 PTEN,
also a key protein in the regulation of the PI3K-AKT pathway, is a
phosphatase that blocks AKT activation by dephosphorylating the
phosphatidylinositol (3,4,5)-trisphosphate (PIP3) to PIP2. Inactivat-
ing mutations and deletions of the PTEN gene are frequent in human
tumors.75 In preclinical models, the importance of PTEN in the devel-
opment of HCC was demonstrated by a mouse model in which the
Pten gene was inactivated, causing steatohepatitis at 10 months of
age and HCC in 100% of animals at 18 months.76 The CDKN1B
gene encodes the cyclin-dependent kinase p27 inhibitor. It controls
the progression of the cell cycle G1 phase by binding to cyclinD-
CDK4 and cyclinE-CDK2. It is, therefore, considered a tumor
suppressor, and it is dysfunctional in cancer through various
mechanisms.77Molecular ThOverall, our results suggest that the action of
miR-199a-3p and anti-miR-221 in preventing
the emergence of HCC occurs through the
control of multiple cancer-associated molecular
pathways, which include PI3K-AKT, WNT-
b-catenin, cell cycle, invasion, and motility.There are no apparent effects on fibrosis and cirrhosis processes,
as suggested by the stable expression of a-Sma after miRNA chal-
lenges. Findings from this study provide the basis for the use of
miRNA-based therapeutics to prevent liver cancer, especially
considering that no apparent toxic effects were detected in treated
mice.
Conclusions
This study describes the development of a mouse model, based on
the TG221 strain, which represents an accurate preclinical example
of hepatocarcinogenesis in a background of cirrhosis, a condition
that mirrors the pathogenesis of most human HCCs. This
model could be used to investigate the mechanisms of hepatocarci-
nogenesis in the cirrhotic liver and to develop preclinical ap-
proaches to prevent or treat liver cancer that arises in the context
of cirrhosis.erapy: Nucleic Acids Vol. 14 March 2019 245
Figure 6. miR-199a-3p and miR-221 Targets Are Deregulated in miRNA-
Treated TG221 Mice
Western blot analysis was performed on cirrhotic tissues (CL) and liver nodules (LN)
extracted from mice treated with anti-miR-221 (AM221) and miR-199a-3p mimic
molecules. The in vivo activity of thesemolecules was confirmed by the deregulation
of important target proteins, as compared to expression in the scramble-treated
control group (CTRL). We observed a reduction in the mechanistic target of rapa-
mycin (mTOR) and p21-activated kinase 4 (PAK4) in tumors from miR-199a-3p-
treated mice (A), and an increase in phosphatase and tensin homolog (PTEN) and
cyclin-dependent kinase inhibitor 1B (P27KIP1) in tumors from AM221-treatedmice
(B). Protein expression data were normalized versus levels of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), and fold-change values with respect to
normal livers (NL) were reported.
Molecular Therapy: Nucleic AcidsHere, by testing anti-miRNA and miRNA mimics as prophylactic
molecules, we demonstrated that miRNA-based treatments did not
cause apparent toxicity, resulted in a reduction in tumor nodule
size, and, most importantly, prevented the malignant transformation
of nodular lesions. These results suggest that the tested molecules
have the potential to reduce the risk of HCC in individuals with
cirrhosis, the main risk factor for HCC in humans.
MATERIALS AND METHODS
In Vivo Studies
The transgenic mouse TG221 has been previously described.16 Both
TG221 and WT mice have the same strain B6D2 (a cross between
C57BL/6J [B6]  DBA/2J [D2]) background. Mice were maintained
in vented cabinets at 24C with a 12-hr light-dark cycle and with
food and water ad libitum. All animals were sacrificed under inhala-
tional anesthetic using isoflurane to minimize suffering. Mice were
subjected to necropsy and tissues were partly fixed in 10% formalin246 Molecular Therapy: Nucleic Acids Vol. 14 March 2019and partly frozen in liquid nitrogen. This study was carried out in
strict accordance with the Guidelines for the Care and Use of Labora-
tory Animals, and the experimental protocols were approved by the
Italian Ministry of Health. To comply with the 2010/63/EU directive
of the European Parliament and Council, enforced by the Italian law
requiring a minimized number of experimental animals, G*Power
(http://www.gpower.hhu.de/) was used to determine the sample
size. All animals were randomly assigned to different treatment
groups at the start of the study. Frozen liver HCCs of DEN-treated
control TG221 mice were obtained from our laboratory tissue bank.
Mice were treated as previously described.20
Induction of Cirrhosis
Liver cirrhosis was induced in both TG221 and WT male mice by
short CCl4 (Sigma-Aldrich, St. Louis, MO, USA) inhalation cycles,
as previously described,29 with some modifications (because of differ-
ences in animal strains). Briefly, WT (5 mice) and TG221 animals (10
mice) were subjected to short-term inhalation of CCl4 via a flowmeter
three times weekly for 14 weeks. A group of WT (5 mice) and TG221
(5 mice) animals was used as an untreated control. TG221 mice were
subjected to a reduced induction protocol (1 L/min), because they did
not tolerate standard CCl4 treatment (2 L/min). The treatment started
at 5–6 weeks of age. Phenobarbital (0.3 g/L) was also administered in
the drinking water to enhance CCl4 hepatotoxicity. After the 14-week
standard induction, mice were monitored for the presence of hepatic
lesions using an ultrasound diagnostic device (Philips IU22). For ul-
trasound analysis, mice were sedated via the intramuscular adminis-
tration of a ketamine (100 mg/kg) and xylazine (10 mg/kg) solution.
All mice with lesions, as documented by ultrasound, were sacrificed,
and liver tissue samples were collected at weeks 22–24 for histological
and molecular analyses. Tumor volume measurement was calculated
according to the following formula: V = (4/3) p (L/2)  (L/2)
(D/2), where L = length and D = depth of the tumor. Data were
obtained by analyzing section images from ultrasonographic exami-
nation videos.78
Quantification of Ascites
At the time of sacrifice, a laparotomy was performed, and four strips
of absorbing paper (5 30 mm) were placed in the abdominal cavity
and removed after 3 min. The amount of ascites was calculated as the
difference in the strip weight before and after placement in the
abdominal cavity.
miRNA-Based Treatments
To evaluate miRNA-based approaches to prevent HCC in the TG221
mouse model, an anti-miRNA oligonucleotide targeting miR-221 (In-
tegrated DNA Technologies, Coralville, IA, USA) and an oligonucleo-
tide that mimics the miR-199a-3p (Axolabs, Kulmbach, Germany)
sequencewere used. Specifically, themiRNA sequenceswere as follows:
(1) anti-miR221, 50-mG*mA*mAmAmCmCmCmAmGmCmAm
GmAmCmAmAmUmGmU*mA*mG*mC*mU-30 (where “m” repre-
sents 20O-methyl RNA bases and “*” represents a phosphothioate
bond); and (2) miR-199a-3p, 50-ACAGUAGUCUGCACAUUG
GUUA-30 (unmodified sequence). Based on the experimental design,
www.moleculartherapy.orgall mice received 14 weeks of CCl4 treatment. From the tenth week of
treatment, mice were subdivided into three groups as follows: seven
mice received a weekly dose of anti-miR-221 (5 mg/kg) for a period
of 10 weeks, six mice received a dose of miR-199a-3p mimic (5 mg/
kg) three times per week for a period of 12 weeks, and nine mice
were treated with a scramble oligonucleotide. In vivo delivery was per-
formed systemically (via intraperitoneal [i.p.] injection) using lipid
nanoparticles as the vehicle.
Lipid Nanoparticles
The lipid components of the nanoparticles were 1,2-dioleoyl-sn-glyc-
ero-3-phosphoethanolamine (DOPE); 1,2-dimyristoyl-sn-glycerol,
methoxypolyethylene glycol (DMG-PEG, molecular weight [MW]
2,000; Avanti Polar Lipids, Alabaster, AL, USA); and linoleic acid
(Sigma-Aldrich). The molar ratio of DOPE:linoleic acid:DMG-PEG
was 50:48:2. The preparation of empty nanoparticles was performed
as previously described.79
Histological Procedures
Tissue samples from at least two representative fragments of each liver
lobewere taken at necropsy,fixed in 10%phosphate-buffered formalin
for 12–24 hr, and then embedded in paraffin. Serial 4-mm sections
were stained with H&E to histologically determine the number and
size of nodules. For Sirius Red staining, 4-mm liver tissue sections
were deparaffinized, rehydrated, and then stained for 1 hr in saturated
picric acid with 0.1 Sirius Red F3BA (Aldrich Chemicals, St. Louis,
MO, USA) at room temperature. Next, the slides were washed twice
with acetic acid solution and finally dehydrated in a graded alcohol se-
ries. Sections were evaluated using an image cytometer consisting of a
single 2/3-in charge-coupled device (CCD) color camera (JVC Profes-
sional Europe, London, UK) mounted on a Leica DMLB microscope
(Leica Microsystems, Wetzlar, Germany) equipped with a motorized
scanning table (Märzhäuser, Wetzlar, Germany) controlled by
Cytometrica software (C&V, Bologna, Italy). The fibrotic area was
quantified based on four different fields (acquired at low magnifica-
tion, 2.5 ) for each slide using ImageJ Software (https://imagej.nih.
gov) and expressed according to the following formula: [collagen
area/(total area  vascular lumen area)]  100.
Morphological Criteria Used for the Classification of Liver
Nodules
Discrete hepatocellular foci (with a diameter <500 mm) that were
cytologically distinguished from the surrounding liver and with ex-
pansile, permeative growth toward the surrounding hepatocellular
plates were classified as dysplastic foci. These were generally localized
around central veins and characterized by enlarged hepatocytes with
fatty changes and/or eosinophilic, dense cytoplasm, with deposits of
hyaline substances or globules. Similar lesions with diameter r >
500 mm were classified as dysplastic nodules (Figure S3). The same
criteria, although with a size cutoff of 1,000 mm, are used in human
pathology.80 Malignant transformation was defined by the develop-
ment of nodule-in-nodule proliferation, with nuclear atypia, an
increased nuclear:cytoplasmic ratio, mitotic activity, and increased
trabeculae width (Figure S4).81RNA Extraction and qPCR Analysis
The total RNA fraction was obtained from samples using Trizol Re-
agent (Invitrogen, Carlsbad, CA, USA). RNA quality was assessed us-
ing the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara,
CA, USA). Quantification of mRNA expression was performed using
EvaGreen-based droplet digital PCR (ddPCR). 200 ng total RNA was
retro-transcribed using random hexamers and oligo dT. After
performing an appropriate dilution, 1 mL cDNA was used for ampli-
fication in a 20-mL reaction volume containing ddPCR EvaGreen
Supermix and specific primers (1864033; Bio-Rad, Hercules, CA,
USA). Droplet generation, cycling conditions, and the enumeration
of positive droplets were performed according to previously described
procedures.82 To normalize the relative abundance of miRNAs, we
used the b-actin gene. For primer sequences, see Table S3.
Gene Expression
RNA was hybridized to an Agilent Whole Mouse Gene Expression
Microarray (G4852A, 8 60K; Agilent Technologies), and one-color
gene expression was performed according to the manufacturer’s pro-
tocol. Labeled cRNA was synthesized from 100 ng total RNA using
the Low RNA Input Linear Amplification kit (Agilent Technologies)
in the presence of cyanine 3-cytosine triphosphate (CTP;
PerkinElmer, Boston, MA, USA). Images generated by the Agilent
scanner and Feature Extraction 10.5 software (Agilent Technologies)
were used to obtain the microarray raw data. Qlucore Omics Explorer
software (QOE) (http://www.qlucore.com/; Qlucore, Lund, Sweden)
was used to analyze the microarray data.
Western Blot Analyses
Tissue samples were collected and immediately frozen in liquid
nitrogen. Samples were homogenized using a syringe in radioimmuno-
precipitation (RIPA) buffer (R0278; Sigma-Aldrich) containing phos-
phatase and protease inhibitors (P2850 and P8340; Sigma-Aldrich)
and processed following the manufacturer’s instructions. Rabbit anti-
bodies against mTOR (7C10, 2983; Cell Signaling Technology, Dan-
vers, MA, USA), PAK4 (3242; Cell Signaling Technology), PTEN
(9552; Cell Signaling Technology), and p27 Kip1 (2552; Cell Signaling
Technology) were diluted in 5% w/v BSA (A4503, Sigma-Aldrich),
1 Tris-buffered saline (TBS), and 0.1% Tween20 (Bio-Rad) and
incubated at 4C for 16 hr. An anti-glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) monoclonal antibody (clone 2D9, TA802519;
OriGene) was used as a housekeeper. For chemiluminescent detection,
a horseradish peroxidase-conjugated secondary antibody (7074; Cell
Signaling Technology) was used in combination with Clarity Western
ECL Blotting Substrate (170-5060; Bio-Rad) for signal detection. Dig-
ital images were acquired using a Chemidoc (Bio-Rad), and signals
were quantified with ImageJ software. Protein expression levels were
normalized according to the expression of the housekeeping protein.
Statistical Analysis
Differences between groups were analyzed using a 2-tailed Student’s
t test. A p value threshold <0.05 was considered significant. When
appropriate, group value was expressed in terms of mean ± SD.
GraphPad Prism 6.0 (GraphPad, La Jolla, CA, USA) was used forMolecular Therapy: Nucleic Acids Vol. 14 March 2019 247
Molecular Therapy: Nucleic Acidsall data analysis. No samples or animals were excluded from the
analyses, and none of the investigators were blinded to group
allocations.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and three tables and
can be found with this article online at https://doi.org/10.1016/j.
omtn.2018.11.018.
AUTHOR CONTRIBUTIONS
E.C., M.D., S.S., andM.N. contributed to overall conception and study
design. E.C., M.D., L.D., P.G., F.G., M.B., C.B., R.C.S., B.K.E., B.Z.,
M.F., and F.F. performed all the experiments and the acquisition,
analysis, and interpretation of data. E.C. and M.N. wrote the manu-
script, which was edited by all co-authors. G.A., S.B., E.M.S., and
L.G. contributed to a critical revision of the manuscript.
CONFLICTS OF INTEREST
All the authors declare no conflicts of interest.
ACKNOWLEDGMENTS
This work was supported by funds from the Italian Association for
Cancer Research (AIRC IG-15615 and AIRC IG-20055), by funds
from the University of Ferrara toM.N., and by a fellowship from Fon-
dazione Umberto Veronesi to L.D. (FUV Fellowship 2018).
REFERENCES
1. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin,
D.M., Forman, D., and Bray, F. (2015). Cancer incidence and mortality worldwide:
sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136,
E359–E386.
2. Fattovich, G., Stroffolini, T., Zagni, I., and Donato, F. (2004). Hepatocellular carci-
noma in cirrhosis: incidence and risk factors. Gastroenterology 127 (5, Suppl 1),
S35–S50.
3. Bugianesi, E. (2007). Non-alcoholic steatohepatitis and cancer. Clin. Liver Dis. 11,
191–207, x–xi.
4. Starley, B.Q., Calcagno, C.J., and Harrison, S.A. (2010). Nonalcoholic fatty liver dis-
ease and hepatocellular carcinoma: a weighty connection. Hepatology 51, 1820–1832.
5. Bruix, J., and Sherman, M.; American Association for the Study of Liver Diseases
(2011). Management of hepatocellular carcinoma: an update. Hepatology 53,
1020–1022.
6. Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.F., de Oliveira,
A.C., Santoro, A., Raoul, J.L., Forner, A., et al.; SHARP Investigators Study Group
(2008). Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359,
378–390.
7. Cheng, A.L., Guan, Z., Chen, Z., Tsao, C.J., Qin, S., Kim, J.S., Yang, T.S., Tak, W.Y.,
Pan, H., Yu, S., et al. (2012). Efficacy and safety of sorafenib in patients with advanced
hepatocellular carcinoma according to baseline status: subset analyses of the phase III
Sorafenib Asia-Pacific trial. Eur. J. Cancer 48, 1452–1465.
8. Llovet, J.M., and Hernandez-Gea, V. (2014). Hepatocellular carcinoma: reasons
for phase III failure and novel perspectives on trial design. Clin. Cancer Res. 20,
2072–2079.
9. Moriguchi, M., Umemura, A., and Itoh, Y. (2016). Current status and future
prospects of chemotherapy for advanced hepatocellular carcinoma. Clin. J.
Gastroenterol. 9, 184–190.
10. Swamy, S.G., Kameshwar, V.H., Shubha, P.B., Looi, C.Y., Shanmugam, M.K., Arfuso,
F., Dharmarajan, A., Sethi, G., Shivananju, N.S., and Bishayee, A. (2017). Targeting248 Molecular Therapy: Nucleic Acids Vol. 14 March 2019multiple oncogenic pathways for the treatment of hepatocellular carcinoma.
Target. Oncol. 12, 1–10.
11. Peng, Y., and Croce, C.M. (2016). The role of MicroRNAs in human cancer. Signal
Transduct. Target. Ther. 1, 15004.
12. Catela Ivkovic, T., Voss, G., Cornella, H., and Ceder, Y. (2017). microRNAs as cancer
therapeutics: A step closer to clinical application. Cancer Lett. 407, 113–122.
13. Gramantieri, L., Fornari, F., Ferracin, M., Veronese, A., Sabbioni, S., Calin, G.A.,
Grazi, G.L., Croce, C.M., Bolondi, L., and Negrini, M. (2009). MicroRNA-221 targets
Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin.
Cancer Res. 15, 5073–5081.
14. Fornari, F., Gramantieri, L., Ferracin, M., Veronese, A., Sabbioni, S., Calin, G.A.,
Grazi, G.L., Giovannini, C., Croce, C.M., Bolondi, L., and Negrini, M. (2008). MiR-
221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular
carcinoma. Oncogene 27, 5651–5661.
15. Garofalo, M., Di Leva, G., Romano, G., Nuovo, G., Suh, S.S., Ngankeu, A., Taccioli, C.,
Pichiorri, F., Alder, H., Secchiero, P., et al. (2009). miR-221&222 regulate TRAIL
resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation.
Cancer Cell 16, 498–509.
16. Callegari, E., Elamin, B.K., Giannone, F., Milazzo, M., Altavilla, G., Fornari, F.,
Giacomelli, L., D’Abundo, L., Ferracin, M., Bassi, C., et al. (2012). Liver tumorige-
nicity promoted by microRNA-221 in a mouse transgenic model. Hepatology 56,
1025–1033.
17. Murakami, Y., Yasuda, T., Saigo, K., Urashima, T., Toyoda, H., Okanoue, T., and
Shimotohno, K. (2006). Comprehensive analysis of microRNA expression patterns
in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25, 2537–2545.
18. Fornari, F., Milazzo, M., Chieco, P., Negrini, M., Calin, G.A., Grazi, G.L., Pollutri, D.,
Croce, C.M., Bolondi, L., and Gramantieri, L. (2010). MiR-199a-3p regulates mTOR
and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells.
Cancer Res. 70, 5184–5193.
19. Ren, K., Li, T., Zhang, W., Ren, J., Li, Z., andWu, G. (2016). miR-199a-3p inhibits cell
proliferation and induces apoptosis by targeting YAP1, suppressing Jagged1-Notch
signaling in human hepatocellular carcinoma. J. Biomed. Sci. 23, 79.
20. Callegari, E., D’Abundo, L., Guerriero, P., Simioni, C., Elamin, B.K., Russo, M., Cani,
A., Bassi, C., Zagatti, B., Giacomelli, L., et al. (2018). miR-199a-3p Modulates MTOR
and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma
Transgenic Mouse Model. Mol. Ther. Nucleic Acids 11, 485–493.
21. Fornari, F., Pollutri, D., Patrizi, C., La Bella, T., Marinelli, S., Casadei Gardini, A.,
Marisi, G., Baron Toaldo, M., Baglioni, M., Salvatore, V., et al. (2017). In hepatocel-
lular carcinoma miR-221 modulates Sorafenib resistance through inhibition of cas-
pase-3-mediated apoptosis. Clin. Cancer Res. 23, 3953–3965.
22. Hou, J., Lin, L., Zhou, W., Wang, Z., Ding, G., Dong, Q., Qin, L., Wu, X., Zheng, Y.,
Yang, Y., et al. (2011). Identification of miRNomes in human liver and hepatocellular
carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma.
Cancer Cell 19, 232–243.
23. Callegari, E., Elamin, B.K., D’Abundo, L., Falzoni, S., Donvito, G., Moshiri, F.,
Milazzo, M., Altavilla, G., Giacomelli, L., Fornari, F., et al. (2013). Anti-tumor activity
of a miR-199-dependent oncolytic adenovirus. PLoS ONE 8, e73964.
24. Newell, P., Villanueva, A., Friedman, S.L., Koike, K., and Llovet, J.M. (2008).
Experimental models of hepatocellular carcinoma. J. Hepatol. 48, 858–879.
25. Heindryckx, F., Colle, I., and Van Vlierberghe, H. (2009). Experimental mouse
models for hepatocellular carcinoma research. Int. J. Exp. Pathol. 90, 367–386.
26. Li, Y., Tang, Z.Y., and Hou, J.X. (2011). Hepatocellular carcinoma: insight from an-
imal models. Nat. Rev. Gastroenterol. Hepatol. 9, 32–43.
27. Marques, T.G., Chaib, E., da Fonseca, J.H., Lourenço, A.C., Silva, F.D., Ribeiro, M.A.,
Jr., Galvão, F.H., and D’Albuquerque, L.A. (2012). Review of experimental models for
inducing hepatic cirrhosis by bile duct ligation and carbon tetrachloride injection.
Acta Cir. Bras. 27, 589–594.
28. Chang, M.L., Yeh, C.T., Chang, P.Y., and Chen, J.C. (2005). Comparison of murine
cirrhosis models induced by hepatotoxin administration and common bile duct liga-
tion. World J. Gastroenterol. 11, 4167–4172.
www.moleculartherapy.org29. Domenicali, M., Caraceni, P., Giannone, F., Baldassarre, M., Lucchetti, G., Quarta, C.,
Patti, C., Catani, L., Nanni, C., Lemoli, R.M., and Bernardi, M. (2009). A novel model
of CCl4-induced cirrhosis with ascites in the mouse. J. Hepatol. 51, 991–999.
30. Sun, Q., Zhang, Y., Liu, F., Zhao, X., and Yang, X. (2007). Identification of candidate
biomarkers for hepatocellular carcinoma through pre-cancerous expression analysis
in an HBx transgenic mouse. Cancer Biol. Ther. 6, 1532–1538.
31. Yamauchi, N., Watanabe, A., Hishinuma, M., Ohashi, K., Midorikawa, Y., Morishita,
Y., Niki, T., Shibahara, J., Mori, M., Makuuchi, M., et al. (2005). The glypican 3 on-
cofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod.
Pathol. 18, 1591–1598.
32. Behnke, M.K., Reimers, M., and Fisher, R.A. (2013). Stem cell and hepatocyte prolif-
eration in hepatitis C cirrhosis and hepatocellular carcinoma: transplant implications.
Ann. Hepatol. 13, 45–53.
33. Jiménez,W., Clária, J., Arroyo, V., and Rodés, J. (1992). Carbon tetrachloride induced
cirrhosis in rats: a useful tool for investigating the pathogenesis of ascites in chronic
liver disease. J. Gastroenterol. Hepatol. 7, 90–97.
34. Domenicali, M., Caraceni, P., Principe, A., Pertosa, A.M., Ros, J., Chieco, P.,
Trevisani, F., Jiménez, W., and Bernardi, M. (2005). A novel sodium overload test
predicting ascites decompensation in rats with CCl4-induced cirrhosis. J. Hepatol.
43, 92–97.
35. Lee, T.Y., Kim, K.T., and Han, S.Y. (2007). Expression of ErbB receptor proteins and
TGF-alpha during diethylnitrosamine-induced hepatocarcinogenesis in the rat liver.
Korean J. Hepatol. 13, 70–80.
36. Schiffer, E., Housset, C., Cacheux, W., Wendum, D., Desbois-Mouthon, C., Rey, C.,
Clergue, F., Poupon, R., Barbu, V., and Rosmorduc, O. (2005). Gefitinib, an EGFR in-
hibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis.
Hepatology 41, 307–314.
37. Luo, M., Yang, F., Huang, S.X., Kuang, Z.P., Luo, X.L., Li, Y.D.,Wu, J.N., and Xie, Y.A.
(2013). Two-stage model of chemically induced hepatocellular carcinoma in mouse.
Oncol. Res. 20, 517–528.
38. Uehara, T., Ainslie, G.R., Kutanzi, K., Pogribny, I.P., Muskhelishvili, L., Izawa, T.,
Yamate, J., Kosyk, O., Shymonyak, S., Bradford, B.U., et al. (2013). Molecular mech-
anisms of fibrosis-associated promotion of liver carcinogenesis. Toxicol. Sci. 132,
53–63.
39. Uehara, T., Pogribny, I.P., and Rusyn, I. (2014). The DEN and CCl4 -Induced Mouse
Model of Fibrosis and Inflammation-Associated Hepatocellular Carcinoma. Curr.
Protoc. Pharmacol. 66, 14.30.1–14.30.10.
40. Reiberger, T., Chen, Y., Ramjiawan, R.R., Hato, T., Fan, C., Samuel, R., Roberge, S.,
Huang, P., Lauwers, G.Y., Zhu, A.X., et al. (2015). An orthotopic mouse model of he-
patocellular carcinoma with underlying liver cirrhosis. Nat. Protoc. 10, 1264–1274.
41. Chung, S.I., Moon, H., Kim, D.Y., Cho, K.J., Ju, H.L., Kim, D.Y., Ahn, S.H., Han, K.H.,
and Ro, S.W. (2016). Development of a transgenic mousemodel of hepatocellular car-
cinoma with a liver fibrosis background. BMC Gastroenterol. 16, 13.
42. Puche, J.E., Saiman, Y., and Friedman, S.L. (2013). Hepatic stellate cells and liver
fibrosis. Compr. Physiol. 3, 1473–1492.
43. Carthy, J.M. (2018). TGFb signaling and the control of myofibroblast differentiation:
Implications for chronic inflammatory disorders. J. Cell. Physiol. 233, 98–106.
44. Liu, H., Wang, S., Ma, W., and Lu, Y. (2015). Transforming Growth Factor b1
Promotes Migration and Invasion of Human Hepatocellular Carcinoma Cells Via
Up-Regulation of Connective Tissue Growth Factor. Cell Biochem. Biophys. 73,
775–781.
45. Fujiwara, N., Friedman, S.L., Goossens, N., and Hoshida, Y. (2018). Risk factors and
prevention of hepatocellular carcinoma in the era of precision medicine. J. Hepatol.
68, 526–549.
46. Choi, J., and Roberts, L.R. (2016). Statins and metformin for chemoprevention of he-
patocellular carcinoma. Clin. Liver Dis. 8, 48–52.
47. Li, J., Hernanda, P.Y., Bramer, W.M., Peppelenbosch, M.P., van Luijk, J., and Pan, Q.
(2015). Anti-tumor effects of metformin in animal models of hepatocellular carci-
noma: a systematic review and meta-analysis. PLoS ONE 10, e0127967.
48. Rawat, D., Shrivastava, S., Naik, R.A., Chhonker, S.K., Mehrotra, A., and Koiri, R.K.
(2018). An Overview of Natural Plant Products in the Treatment of HepatocellularCarcinoma. Anticancer Agents Med. Chem. Published online June 3, 2018. https://
doi.org/10.2174/1871520618666180604085612.
49. Bishayee, A., Waghray, A., Barnes, K.F., Mbimba, T., Bhatia, D., Chatterjee, M., and
Darvesh, A.S. (2010). Suppression of the inflammatory cascade is implicated in re-
sveratrol chemoprevention of experimental hepatocarcinogenesis. Pharm. Res. 27,
1080–1091.
50. Afrin, R., Arumugam, S., Rahman, A., Wahed, M.I., Karuppagounder, V., Harima,
M., Suzuki, H., Miyashita, S., Suzuki, K., Yoneyama, H., et al. (2017). Curcumin ame-
liorates liver damage and progression of NASH in NASH-HCC mouse model
possibly by modulating HMGB1-NF-kB translocation. Int. Immunopharmacol. 44,
174–182.
51. Tacke, F., and Weiskirchen, R. (2018). An update on the recent advances in antifi-
brotic therapy. Expert Rev. Gastroenterol. Hepatol. 12, 1143–1152.
52. Liu, W., Nakamura, H., Tsujimura, T., Cheng, J., Yamamoto, T., Iwamoto, Y.,
Imanishi, H., Shimomura, S., Yamamoto, T., Hirasawa, T., et al. (2006).
Chemoprevention of spontaneous development of hepatocellular carcinomas in fatty
liver Shionogi mice by a cyclooxygenase-2 inhibitor. Cancer Sci. 97, 768–773.
53. Lu, S.C., Ramani, K., Ou, X., Lin, M., Yu, V., Ko, K., Park, R., Bottiglieri, T.,
Tsukamoto, H., Kanel, G., et al. (2009). S-adenosylmethionine in the chemopreven-
tion and treatment of hepatocellular carcinoma in a rat model. Hepatology 50,
462–471.
54. Callegari, E., Gramantieri, L., Domenicali, M., D’Abundo, L., Sabbioni, S., and
Negrini, M. (2015). MicroRNAs in liver cancer: a model for investigating pathogen-
esis and novel therapeutic approaches. Cell Death Differ. 22, 46–57.
55. Moles, R. (2017). MicroRNAs-based Therapy: A Novel and Promising Strategy for
Cancer Treatment. MicroRNA 6, 102–109.
56. Pineau, P., Volinia, S., McJunkin, K., Marchio, A., Battiston, C., Terris, B.,
Mazzaferro, V., Lowe, S.W., Croce, C.M., and Dejean, A. (2010). miR-221 overexpres-
sion contributes to liver tumorigenesis. Proc. Natl. Acad. Sci. USA 107, 264–269.
57. Park, J.K., Kogure, T., Nuovo, G.J., Jiang, J., He, L., Kim, J.H., Phelps, M.A., Papenfuss,
T.L., Croce, C.M., Patel, T., and Schmittgen, T.D. (2011). miR-221 silencing blocks
hepatocellular carcinoma and promotes survival. Cancer Res. 71, 7608–7616.
58. Liu, Z., Wang, C., Jiao, X., Zhao, S., Liu, X., Wang, Y., and Zhang, J. (2016). miR-221
promotes growth and invasion of hepatocellular carcinoma cells by constitutive acti-
vation of NFkB. Am. J. Transl. Res. 8, 4764–4777.
59. Jia, X.Q., Cheng, H.Q., Qian, X., Bian, C.X., Shi, Z.M., Zhang, J.P., Jiang, B.H., and
Feng, Z.Q. (2012). Lentivirus-mediated overexpression of microRNA-199a inhibits
cell proliferation of human hepatocellular carcinoma. Cell Biochem. Biophys. 62,
237–244.
60. Ghosh, A., Dasgupta, D., Ghosh, A., Roychoudhury, S., Kumar, D., Gorain, M., Butti,
R., Datta, S., Agarwal, S., Gupta, S., et al. (2017). MiRNA199a-3p suppresses tumor
growth, migration, invasion and angiogenesis in hepatocellular carcinoma by target-
ing VEGFA, VEGFR1, VEGFR2, HGF and MMP2. Cell Death Dis. 8, e2706.
61. Guan, J., Liu, Z., Xiao, M., Hao, F., Wang, C., Chen, Y., Lu, Y., and Liang, J. (2017).
MicroRNA-199a-3p inhibits tumorigenesis of hepatocellular carcinoma cells by tar-
geting ZHX1/PUMA signal. Am. J. Transl. Res. 9, 2457–2465.
62. Varshney, A., Panda, J.J., Singh, A.K., Yadav, N., Bihari, C., Biswas, S., Sarin, S.K., and
Chauhan, V.S. (2018). Targeted delivery of microRNA-199a-3p using self-assembled
dipeptide nanoparticles efficiently reduces hepatocellular carcinoma in mice.
Hepatology 67, 1392–1407.
63. Kumar, R., Sanawar, R., Li, X., and Li, F. (2017). Structure, biochemistry, and biology
of PAK kinases. Gene 605, 20–31.
64. Paliouras, G.N., Naujokas, M.A., and Park, M. (2009). Pak4, a novel Gab1 binding
partner, modulates cell migration and invasion by the Met receptor. Mol. Cell.
Biol. 29, 3018–3032.
65. Aspenström, P., Fransson, A., and Saras, J. (2004). Rho GTPases have diverse effects
on the organization of the actin filament system. Biochem. J. 377, 327–337.
66. Tyagi, N., Bhardwaj, A., Singh, A.P., McClellan, S., Carter, J.E., and Singh, S. (2014).
p-21 activated kinase 4 promotes proliferation and survival of pancreatic cancer cells
through AKT- and ERK-dependent activation of NF-kB pathway. Oncotarget 5,
8778–8789.Molecular Therapy: Nucleic Acids Vol. 14 March 2019 249
Molecular Therapy: Nucleic Acids67. Wells, C.M., Abo, A., and Ridley, A.J. (2002). PAK4 is activated via PI3K in HGF-
stimulated epithelial cells. J. Cell Sci. 115, 3947–3956.
68. Kumar, R., and Li, D.Q. (2016). PAKs in Human Cancer Progression: From Inception
to Cancer Therapeutic to Future Oncobiology. Adv. Cancer Res. 130, 137–209.
69. Davis, S.J., Sheppard, K.E., Pearson, R.B., Campbell, I.G., Gorringe, K.L., and
Simpson, K.J. (2013). Functional analysis of genes in regions commonly amplified
in high-grade serous and endometrioid ovarian cancer. Clin. Cancer Res. 19,
1411–1421.
70. Greenman, C., Stephens, P., Smith, R., Dalgliesh, G.L., Hunter, C., Bignell, G., Davies,
H., Teague, J., Butler, A., Stevens, C., et al. (2007). Patterns of somatic mutation in
human cancer genomes. Nature 446, 153–158.
71. Whale, A.D., Dart, A., Holt, M., Jones, G.E., and Wells, C.M. (2013). PAK4 kinase
activity and somatic mutation promote carcinoma cell motility and influence inhib-
itor sensitivity. Oncogene 32, 2114–2120.
72. Parsons, D.W., Wang, T.L., Samuels, Y., Bardelli, A., Cummins, J.M., DeLong, L.,
Silliman, N., Ptak, J., Szabo, S., Willson, J.K., et al. (2005). Colorectal cancer: muta-
tions in a signalling pathway. Nature 436, 792.
73. Alayev, A., and Holz, M.K. (2013). mTOR signaling for biological control and cancer.
J. Cell. Physiol. 228, 1658–1664.
74. Zucman-Rossi, J., Villanueva, A., Nault, J.C., and Llovet, J.M. (2015). Genetic
Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology 149,
1226–1239.e4.
75. Hollander, M.C., Blumenthal, G.M., and Dennis, P.A. (2011). PTEN loss in the con-
tinuum of common cancers, rare syndromes and mouse models. Nat. Rev. Cancer 11,
289–301.250 Molecular Therapy: Nucleic Acids Vol. 14 March 201976. Horie, Y., Suzuki, A., Kataoka, E., Sasaki, T., Hamada, K., Sasaki, J., Mizuno, K.,
Hasegawa, G., Kishimoto, H., Iizuka, M., et al. (2004). Hepatocyte-specific Pten defi-
ciency results in steatohepatitis and hepatocellular carcinomas. J. Clin. Invest. 113,
1774–1783.
77. le Sage, C., Nagel, R., and Agami, R. (2007). Diverse ways to control p27Kip1 func-
tion: miRNAs come into play. Cell Cycle 6, 2742–2749.
78. Faustino-Rocha, A.I., Gama, A., Oliveira, P.A., Alvarado, A., Fidalgo-Gonçalves, L.,
Ferreira, R., and Ginja, M. (2016). Ultrasonography as the Gold Standard for
In Vivo Volumetric Determination of Chemically-induced Mammary Tumors.
In Vivo 30, 465–472.
79. Huang, X., Schwind, S., Yu, B., Santhanam, R., Wang, H., Hoellerbauer, P., Mims, A.,
Klisovic, R., Walker, A.R., Chan, K.K., et al. (2013). Targeted delivery of microRNA-
29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic
strategy in acute myeloid leukemia. Clin. Cancer Res. 19, 2355–2367.
80. Wanless, I.R., and Party, I.W.; International Working Party (1995). Terminology of
nodular hepatocellular lesions. Hepatology 22, 983–993.
81. Neoplasia, I.C.G.H.; International Consensus Group for Hepatocellular
NeoplasiaThe International Consensus Group for Hepatocellular Neoplasia (2009).
Pathologic diagnosis of early hepatocellular carcinoma: a report of the international
consensus group for hepatocellular neoplasia. Hepatology 49, 658–664.
82. Miotto, E., Saccenti, E., Lupini, L., Callegari, E., Negrini, M., and Ferracin, M. (2014).
Quantification of circulating miRNAs by droplet digital PCR: comparison of
EvaGreen- and TaqMan-based chemistries. Cancer Epidemiol. Biomarkers Prev.
23, 2638–2642.
